Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

XERS 11.26.2024

Full Press ReleaseSEC FilingsOur XERS Tweets

About Gravity Analytica

Recent News

  • 01.10.2025 - Xeris Expects to Exceed Full-Year 2024 Financial Guidance
  • 01.06.2025 - Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Recent Filings

  • 01.10.2025 - 8-K Current report
  • 01.10.2025 - EX-99.1 EX-99.1
  • 01.07.2025 - 4 Statement of changes in beneficial ownership of securities

CHICAGO--(BUSINESS WIRE)--Nov. 26, 2024--Xeris Biopharma Holdings, Inc.(Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference onDecember 3, 2024at8:00am Eastern Time.

A live webcast of the event will be available on the 'Events & Presentations' section of Xeris’ Investor Relations website atwww.xerispharma.com. A replay of the webcast will be available for 30 days.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs to bring new products forward using its proprietary formulation technology platforms, XeriSol® and XeriJect®, supporting long-term product development and commercial success.

Xeris Biopharma Holdingsis headquartered inChicago, IL.For more information, visitwww.xerispharma.com, or follow us onX,LinkedIn, orInstagram.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241125772487/en/

Investor ContactAllison WeySenior Vice President, Investor Relations and Corporate Communicationsawey@xerispharma.com

Source:Xeris Biopharma

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com